--- title: "Crosstree Capital: Expert Investment Banking Services for Health Science" description: Access market experts, explore greater insights, and tap an extensive network of industry relationships. --- # Investment Banking Services that Drive Transformative Transactions ### Our experienced senior bankers provide expert M&A advisory services to health sciences firms and investors seeking superior outcomes. ### 200+ Deals Closed ### 20+ Transactions Per Year ### 100% Health Sciences Transactions ## M&A Advisory We are part of the fabric of the industries we serve. As a global M&A investment banking advisory firm, our services are delivered by a team of experienced senior bankers who have spent their careers developing deep professional relationships and building in-depth knowledge of the companies, trends and insights relevant to our core areas of industry focus.  ![M&A - Image](https://www.crosstreecapital.com/hubfs/theme-crosstree/images/M%26A%20-%20Image.jpg) ## Proven Process Crosstree executes against, “[The Standard](https://www.crosstreecapital.com/careers/lifeatcrosstree#standard),” a system designed to set the bar for quality, consistency, and outcomes. 01 #### 360° Storytelling With a solid foundation of data and a deep understanding of your industry, we build a clear, elegant story of substance to explain your value to potential buyers.  02 #### Marketing Strategy We match your company’s distinguishing characteristics and unique value proposition with market trends and buyer/investor fit, using thoughtful, disciplined qualification and scoring rigor 03 #### Competitive Bidding Our reputation as expert health sciences advisors with high quality deals increases potential buyer confidence and attention 04 #### Exceptional Outcomes We consistently and predictably achieve spike valuations and exceptional financial results for our clients. ![M&A - Process](https://www.crosstreecapital.com/hubfs/theme-crosstree/images/M%26A%20-%20Process.jpg) ## Crosstree’s Client Outcomes Consistently Exceed Industry Benchmarks Crosstree’s deep industry focus fosters efficient project execution. Our relationships with investors and strategic buyers are unmatched in the industry. ![M&A - Higher Valuations](https://www.crosstreecapital.com/hs-fs/hubfs/theme-crosstree/images/M%26A%20-%20Higher%20Valuations.jpg?length=387&name=M&A%20-%20Higher%20Valuations.jpg) #### Achieve higher valuations Our deals consistently achieve “spike valuations” through concise articulation of client value propositions, credible financial and technical support, and thoughtful alignment of industry trends. ![M&A - Confident](https://www.crosstreecapital.com/hs-fs/hubfs/theme-crosstree/images/M%26A%20-%20Confident.jpg?length=387&name=M&A%20-%20Confident.jpg) #### Be confident in your success Our culmination of industry expertise that leverages market data, trends, and a high-profile network, drives an outstanding closing rate of almost 90%. ![M&A - Accelerate](https://www.crosstreecapital.com/hs-fs/hubfs/theme-crosstree/images/M%26A%20-%20Accelerate.jpg?length=387&name=M&A%20-%20Accelerate.jpg) #### Accelerate your closings By combining technology, structured project management methodology, and a focused process approach, We close transactions faster — with less resourcing strain on clients — compared to traditional investment banks. ## Client Testimonials ![Ascent logo](https://www.crosstreecapital.com/hs-fs/hubfs/Deal%20Logos/Ascent%20logo.png?width=381&height=126&name=Ascent%20logo.png) > I really can’t speak highly enough of the expert, intelligent and dedicated advocacy of Crosstree that brought about a truly tremendous result for Ascent. The Crosstree team was superb in all aspects of setting up, negotiating and finalizing a really fantastic deal. We particularly appreciated their willingness to work flexibly with Ascent as we were undergoing considerable growing pains, especially related to financial management which was such a critical aspect. The Ascent team was really lucky and is very grateful for having had access to such expert, dedicated and adept support. ![John-Winebarger_photo-circle](https://www.crosstreecapital.com/hubfs/Testimonials/Headshots/John-Winebarger_photo-circle.png) ##### John Winebarger CEO and Founder ![pharmasol_logo-rgb-768x204](https://www.crosstreecapital.com/hs-fs/hubfs/Testimonials/Logos/pharmasol_logo-rgb-768x204.png?width=768&height=204&name=pharmasol_logo-rgb-768x204.png) > Crosstree was recommended to us by a trusted partner who had previously worked closely with them on successful deals. We are very pleased to have listened to this advice and have been guided and supported throughout the merger process over the last months. The team brought a strong understanding of our industry segment, finding an impressive list of prospective buyers, and then ensured that during the due diligence and closing phases we hit each of the critical milestones on time. ![Tim-Billington-Pharmasol](https://www.crosstreecapital.com/hubfs/Testimonials/Headshots/Tim-Billington-Pharmasol.png) ##### Tim Billington Chief Sales Officer ![download-1-e1633377000585](https://www.crosstreecapital.com/hs-fs/hubfs/Testimonials/Logos/download-1-e1633377000585.png?width=225&height=110&name=download-1-e1633377000585.png) > After growing Quartesian into one of the largest independent biometrics companies in the world, we realized the next chapter of our journey would require a strong financial partner, but finding the right partner would be a challenge. Crosstree put their expertise in the pharma services space to work for us, helping us identify Summit Partners – the perfect fit for all of our stakeholders. The resulting deal led to Quartesian becoming a foundational pillar in Veranex, the first concept-to-commercialization global service provider in medtech. ![Soumitra-Chowdhury-website](https://www.crosstreecapital.com/hubfs/Testimonials/Headshots/Soumitra-Chowdhury-website.png) ##### Soumitra Chowdhury Executive VP, Data & Analytics / 3 ##### Recent M&A Transactions [![ROI Healthcare Solutions Acquired by Acuvance, a Portfolio Company of Trinity Hunt](https://www.crosstreecapital.com/hubfs/Tombstone_ROI_01_28_2026-1.png) ### ROI Healthcare Solutions Acquired by Acuvance, a Portfolio Company of Trinity Hunt ](https://www.crosstreecapital.com/deals/roi-healthcare-solutions-acquired-by-acuvance-a-portfolio-company-of-trinity-hunt?hsLang=en) [![IPeople Acquired by RLDatix, a Portfolio Company of Five Arrows and TA Associates ](https://www.crosstreecapital.com/hubfs/Deal%20Insight%20Tombstone%20iPeople%20(3).png) ### IPeople Acquired by RLDatix, a Portfolio Company of Five Arrows and TA Associates ](https://www.crosstreecapital.com/deals/ipeople-acquired-by-rldatix-a-portfolio-company-of-five-arrows-and-ta-associates?hsLang=en) [![Deep 6 AI Acquired by Tempus ](https://www.crosstreecapital.com/hubfs/Deep%206%20AITempus%20(315%20x%20315%20px).png) ### Deep 6 AI Acquired by Tempus  ](https://www.crosstreecapital.com/deals/deep-6-ai-acquired-by-tempus?hsLang=en) [![Sengenics, a Portfolio Company of Summa Equity, Acquired by Standard BioTools](https://www.crosstreecapital.com/hubfs/Deal%20Insight%20Tombstone%20sengenics%20(2).png) ### Sengenics, a Portfolio Company of Summa Equity, Acquired by Standard BioTools ](https://www.crosstreecapital.com/deals/sengenics-a-portfolio-company-of-summa-equity-acquired-by-standard-biotools?hsLang=en) [![Actigraph, a Portfolio Company of Archimed, Acquired Biofourmis’ Life Science Business](https://www.crosstreecapital.com/hubfs/Deal%20Insight%20Tombstone%20ActiGraph%20(1).png) ### Actigraph, a Portfolio Company of Archimed, Acquired Biofourmis’ Life Science Business ](https://www.crosstreecapital.com/deals/actigraph-a-portfolio-company-of-archimed-acquired-biofourmis-life-science-business?hsLang=en) [![Bio-Techne Divested Assets of Its Subsidiary, Atlanta Biologicals, to GeminiBio](https://www.crosstreecapital.com/hubfs/Deal%20Insight%20Tombstone%20Biotechne.png) ### Bio-Techne Divested Assets of Its Subsidiary, Atlanta Biologicals, to GeminiBio ](https://www.crosstreecapital.com/deals/bio-techne-divested-assets-of-its-subsidiary-atlanta-biologicals-to-geminibio?hsLang=en) [![Anju Software Acquired by Valsoft Corporation to Grow eClinical and Commercialization Capabilities](https://www.crosstreecapital.com/hubfs/Deal%20Insight%20Tombstone%20Anju%20+%20Valsoft.png) ### Anju Software Acquired by Valsoft Corporation to Grow eClinical and Commercialization Capabilities ](https://www.crosstreecapital.com/deals/anju-software-acquired-by-valsoft-corporation-to-grow-eclinical-and-commercialization-capabilities?hsLang=en) [![Pinnacle Clinical Research Acquired The Cognitive and Research Center of New Jersey to Expand Clinical Trial Site Network](https://www.crosstreecapital.com/hubfs/Deal%20Insight%20Campaign%20LVCCRCNJ%20-%20Social.png) ### Pinnacle Clinical Research Acquired The Cognitive and Research Center of New Jersey to Expand Clinical Trial Site Network ](https://www.crosstreecapital.com/deals/pinnacle-clinical-research-a-portfolio-company-of-longuevue-capital-acquired-the-cognitive-and-research-center-of-new-jersey-to-expand-clinical-trial-site-network-to-expand-its-cns-trial-execution-capabilities?hsLang=en) [![Pinnacle Clinical Research Acquires Kerwin Medical Center to Bolster Clinical Trial Site Network](https://www.crosstreecapital.com/hubfs/Deal%20Insight%20Campaign%20LVCKerwin%20-%20Social.png) ### Pinnacle Clinical Research Acquires Kerwin Medical Center to Bolster Clinical Trial Site Network ](https://www.crosstreecapital.com/deals/pinnacle-clinical-research-a-portfolio-company-of-longvue-capital-acquires-kerwin-medical-center-to-bolster-clinical-trial-site-network-and-trial-execution-capabilities?hsLang=en) [![BBI Solutions, a Portfolio Company of Novo Holdings, Acquired IBEX Technologies Inc. to Bolster Recombinant Protein Offering](https://www.crosstreecapital.com/hubfs/Deal%20Insight%20Campaign%20Tombstone%20-%20BBIIBEX.png) ### BBI Solutions, a Portfolio Company of Novo Holdings, Acquired IBEX Technologies Inc. to Bolster Recombinant Protein Offering ](https://www.crosstreecapital.com/deals/bbi-solutions-a-portfolio-company-of-novo-holdings-acquired-ibex-technologies-inc?hsLang=en) [![Myonex Acquired Creapharm's Clinical & Commercial Packaging and Bioservices Business Units to Expand Clinical Trial Supply Services and Gain of Foothold in Europe](https://www.crosstreecapital.com/hubfs/Deal%20Insight%20Campaign%20Myonex%20+%20Creapharm-%20Social%20V2.png) ### Myonex Acquired Creapharm's Clinical & Commercial Packaging and Bioservices Business Units to Expand Clinical Trial Supply Services and Gain of Foothold in Europe ](https://www.crosstreecapital.com/deals/myonex-acquired-creapharms-clinical-and-commercial-packaging-and-bioservices-business-units?hsLang=en) [![Myonex Acquired SaveWay Compounding Pharmacy to Expand and Bolster its Clinical Trial Services Across the US](https://www.crosstreecapital.com/hubfs/Deal%20Insight%20Campaign%20Myonex%20+%20Creapharm-%20Social%20V2%20(1).png) ### Myonex Acquired SaveWay Compounding Pharmacy to Expand and Bolster its Clinical Trial Services Across the US ](https://www.crosstreecapital.com/deals/myonex-acquired-saveway-compounding-pharmacy?hsLang=en) [![Calyx has divested its 'Enterprise Technology' Division to Ennov, to Enhance Ennov’s portfolio of eClinical and eRegulatory Software Solutions](https://www.crosstreecapital.com/hubfs/Deal%20Insight%20Campaign%20Tombstone%20-%20Calyx%20(Social%20Sized).V3-1.png) ### Calyx has divested its 'Enterprise Technology' Division to Ennov, to Enhance Ennov’s portfolio of eClinical and eRegulatory Software Solutions ](https://www.crosstreecapital.com/deals/calyx-has-divested-its-enterprise-technology-division-to-ennov-to-enhance-ennovs-portfolio-of-eclinical-and-eregulatory-software-solutions?hsLang=en) [![physIQ Acquired by Prolaio to Enhance its Next-Gen Connected Heart Care Technology for Clinical Care and Research](https://www.crosstreecapital.com/hubfs/Deal%20Campaign%20Tombstone%20-%20PhysIQ%20(Social%20Sized)%20(1).png) ### physIQ Acquired by Prolaio to Enhance its Next-Gen Connected Heart Care Technology for Clinical Care and Research ](https://www.crosstreecapital.com/deals/physiq-acuired-by-prolaio?hsLang=en) [![Continuum Clinical, a BC Worldwide company, Acquired by Spectrum Science, a Portfolio Company of Knox Lane, to Bolster Patient Engagement Capabilities](https://www.crosstreecapital.com/hubfs/Deal%20Insight%20Campaign%20Tombstone%20-%20Continuum%20Clinical%20(Social%20Sized).png) ### Continuum Clinical, a BC Worldwide company, Acquired by Spectrum Science, a Portfolio Company of Knox Lane, to Bolster Patient Engagement Capabilities ](https://www.crosstreecapital.com/deals/continuum-clinical-a-bc-worldwide-company-acquired-by-spectrum-science-a-portfolio-company-of-knox-lane-to-bolster-patient-engagement-capabilities?hsLang=en) [![Yecuris Corporation Acquired by Janvier Group to Expand Preclinical Service Offering Internationally](https://www.crosstreecapital.com/hubfs/Deal%20Insight%20Campaign%20Tombstone%20-%20Yecuris%20(Social%20Sized)%20(NEW).png) ### Yecuris Corporation Acquired by Janvier Group to Expand Preclinical Service Offering Internationally ](https://www.crosstreecapital.com/deals/yecuris-acquired-by-janvier-group?hsLang=en) [![Alpha IRB Acquired by Sabai Global, a Portfolio Company of Thompson Street Capital, to Expand IRB Capabilities](https://www.crosstreecapital.com/hubfs/theme-crosstree/deals/Deal-Insight-Campaign-Tombstone-Alpha-IRBSabai-Global-Social-Sized.png) ### Alpha IRB Acquired by Sabai Global, a Portfolio Company of Thompson Street Capital, to Expand IRB Capabilities ](https://www.crosstreecapital.com/deals/alpha-irb-acquired-by-sabai-global-a-portfolio-company-of-thompson-street-capital-to-expand-irb-capabilities?hsLang=en) [![VaxTRIALS Acquired by Emmes, a portfolio company of New Mountain Capital, to Expand Vaccine and Clinical Trial Site Capabilities](https://www.crosstreecapital.com/hubfs/2024%20-%20Vax%20Trials%20-%20Emmes.png) ### VaxTRIALS Acquired by Emmes, a portfolio company of New Mountain Capital, to Expand Vaccine and Clinical Trial Site Capabilities ](https://www.crosstreecapital.com/deals/vaxtrials-acuired-by-emmes?hsLang=en) [![Monroe Biomedical Research Acquired by New Harbor Capital in a First Step to Build-out a Clinical Research Site Platform](https://www.crosstreecapital.com/hubfs/2024%20-%20mbr%20-%20New%20harbor.png) ### Monroe Biomedical Research Acquired by New Harbor Capital in a First Step to Build-out a Clinical Research Site Platform ](https://www.crosstreecapital.com/deals/monroe-biomedical-research-acquired-by-new-harbor-capital-in-a-first-step-to-build-out-a-clinical-research-site-platform?hsLang=en) [![QDx Pathology, a Portfolio Company of Hadley Capital, Acquired by LabGenomics to Expand Esoteric Testing Capabilities Globally](https://www.crosstreecapital.com/hubfs/2024%20-%20QDX%20-%20Hadley%20-%20LabGenomics.png) ### QDx Pathology, a Portfolio Company of Hadley Capital, Acquired by LabGenomics to Expand Esoteric Testing Capabilities Globally ](https://www.crosstreecapital.com/deals/qdx-pathology-a-portfolio-company-of-hadley-capital-acquired-by-labgenomics-to-expand-esoteric-testing-capabilities-globally?hsLang=en) [View all deals](https://www.crosstreecapital.com/deals?hsLang=en) ## Sound strategies that yield superior outcomes. [ Consult Crosstree ](https://www.crosstreecapital.com/contact?hsLang=en)